BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Lipitor
,
rs3825942
,
LEP
,
Apoptosis
,
Leukemia
,
Kidney
,
Personalized medicine
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
AKT 2
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Hepatocellular carcinoma HEPG2 cells treated with small molecule perturbagens
L1000 CMAP - Breast adenocarcinoma SKBR3 cells treated with small molecule perturbagens
Explore Curated Studies Results
Literature
Most Relevant Literature
Activity-induced synaptic structural modifications by Akt.
A multi-layered network model identifies Akt1 as a common modulator of neurodegeneration.
Identification of XAF1 as an endogenous AKT inhibitor.
Redundant roles of AKT1 and AKT2 in fertility, estrous cyclicity and endometrial gland development.
Enhanced Akt3 kinase activity reduces atherosclerosis in hyperlipidemic mice in a gender-dependent m…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase I Dose Escalation Study With an Allosteric AKT 1/2 Inhibitor in Patients
Phase I Study of Palomid 529 a Dual TORC1/2 Inhibitor of the PI3K/Akt/mTOR Pathway for Advanced Neov…
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast …
Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Ca…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ